Close
Nordic 9Nordic 9

ALS Investment Fund (investor - Venture Capital)

Netherlands alsinvestmentfund.com
See something wrong or missing? Let us know
Offices:Amsterdam

The ALS Investment Fund is a Dutch investor that supports and finances biotech companies

Average round investment:136.74M USD
Average number per year:1.0
Distribution: 2023 (1)
Portfolio companies: Netherlands VectorY Therapeutics
Mostly invests in: Netherlands Netherlands (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to ALS Investment Fund

Name Criteria
United States Bluebird Ventures
73%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Arab Emirates Chimera Investment
73%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United Kingdom AstraZeneca
72%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Denmark ATP
72%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United Kingdom LGT Lightstone
71%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States TPG
71%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Sweden AP3
70%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Nikon
70%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States National Resilience
70%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Alpha Wave Global
70%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top